Compare · DXCM vs IVF
DXCM vs IVF
Side-by-side comparison of DexCom Inc. (DXCM) and INVO Fertility Inc. (IVF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IVF operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.67B, about 8949.5x IVF ($2.6M).
- DXCM has been more active in the news (8 items in the past 4 weeks vs 2 for IVF).
- DXCM has more recent analyst coverage (25 ratings vs 0 for IVF).
- Company
- DexCom Inc.
- INVO Fertility Inc.
- Price
- -
- -
- Market cap
- $23.67B
- $2.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 8
- 2
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
Latest IVF
- INVO Fertility Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
- SEC Form SCHEDULE 13G filed by INVO Fertility Inc.
- SEC Form NT 10-K filed by INVO Fertility Inc.
- INVO Fertility Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
- INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic
- INVO Fertility's Wisconsin Clinic Joins Progyny Network
- INVO Fertility Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic "Family Beginnings"